14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
SYK vs PHG
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs PHG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SYK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)
SYK Overall Winner
6-Pillar Tally: SYK 5 – 1 PHG
Matrix Metrics: SYK 7 – 3 PHG
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin).
SYK
NYSE
Head-to-Head Winner
Stryker Corporation
Surgical & Medical Instruments & Apparatus
Market Cap
$118.9B
TTM Revenue
$26.3B
Forward P/E
19.0x
Beta / 30D Vol
0.22β · 50% Vol
Unified Composite Score
46.5 / 100
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
PHG
NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Market Cap
$29.6B
TTM Revenue
$8.71B
Forward P/E
14.9x
Beta / 30D Vol
0.73β · 38% Vol
Unified Composite Score
28.4 / 100
SELL
Tech 50.0
Fund 23.0
Flow 54.0
Mom 11.1
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.4% over 20 days), RSI 71
RSI-14: 71.0 · SMA20: $28.51 · SMA50: $26.23
6-Pillar Scorecard Institutional Category Breakdown (SYK 5 – 1 PHG)
Columns: Metric · SYK · PHG
1. Valuation Multiples
PHG
Forward P/E
19.0x
14.9x
Trailing P/E
33.3x
63.2x
PEG Ratio
1.54x
0.90x
EV / Revenue
5.0x
3.7x
2. Growth & Scale
SYK
Revenue Growth (YoY)
+7.6%
+2.1%
Earnings Growth (YoY)
-11.7%
-85.4%
TTM Revenue (USD)
$26.3B
$8.71B
Market Cap
$118.9B
$29.6B
3. Profitability & Quality
SYK
Gross Margin
65.7%
46.4%
Operating Margin
24.0%
8.8%
Net Profit Margin
13.8%
5.4%
Return on Equity (ROE)
16.0%
8.6%
4. Balance Sheet & Cash Flow
SYK
Cash Generation (TTM)
$4.57B
$895M
Cash Flow Margin
17.4%
10.3%
Net Cash / Leverage
$11.7B Net Debt (0.64x D/E)
$2.64B Net Debt (0.70x D/E)
Dividend Yield
1.10%
None (0.00%)
5. Options & Positioning
SYK
Options Structure Phase
SURGE
SURGE
Current IV / %ile
28.1% (5th %ile)
25.8% (2nd %ile)
Put/Call OI Skew
0.30x (Call-Skewed)
0.30x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
SYK
OpEx & R&D Intensity
41.7% of Rev ($11.0B)
37.6% of Rev ($3.27B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Concentrated Oligopoly Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SYK (7) vs PHG (3)
Institutional Metric
SYK
PHG
Criterion
Row Edge
Market Capitalization
Scale
$118.9B
$29.6B
Larger Scale
SYK
Trailing P/E Ratio
Valuation
33.3x
63.2x
Lower Multiple
SYK
Forward P/E Ratio
Valuation
19.0x
14.9x
Lower Multiple
PHG
Revenue Growth (YoY)
Growth
+7.6%
+2.1%
Higher Growth
SYK
Operating Margin (TTM)
Profitability
24.0%
8.8%
Higher Margin
SYK
Net Profit Margin
Profitability
13.8%
5.4%
Higher Margin
SYK
Return on Equity (ROE)
Capital Efficiency
16.0%
8.6%
Higher ROE
SYK
52-Week Range Position
Momentum
36% ($267–$389)
67% ($24–$33)
Stronger Trend
PHG
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol
0.73β · 38% Vol
Lower Realized Risk
PHG
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD)
28.4 / 100 (SELL)
Higher Composite
SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B
$8.71B
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7%
46.4%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev
0.90x PEG · 3.7x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E))
$895M ($2.64B Net Debt (0.70x D/E))
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
PHG +11.9 pp
SYK:
+5.47%
·
PHG:
+17.37%
3M Horizon
PHG +17.69 pp
SYK:
-6.21%
·
PHG:
+11.48%
6M Horizon
PHG +16.75 pp
SYK:
-0.78%
·
PHG:
+15.97%
1Y Horizon
PHG +21.23 pp
SYK:
-16.77%
·
PHG:
+4.46%
Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
Split-Invariant USD Revenue & Operating Margin (%)
Period
SYK Revenue
PHG Revenue
SYK Op. Margin
PHG Op. Margin
Margin Leader
Q3 '25
$24.2B
$8.44B
19.9%
7.7%
SYK
Q4 '25
$28.7B
$10.0B
25.3%
11.1%
SYK
Q1 '26
$24.1B
$7.66B
15.5%
6.2%
SYK
Q2 '26
$26.4B
$8.55B
25.2%
14.0%
SYK
Q3 '26
$26.1B
$8.62B
20.4%
3.8%
SYK
SYK
SURGE
8d in phase · OBV DISTRIBUTION
Current IV
28.1%
IV Percentile
5th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
PHG
SURGE
8d in phase · OBV DISTRIBUTION
Current IV
25.8%
IV Percentile
2nd %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
SYK Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment
41.7% of Rev ($11.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
PHG Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $29.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment
37.6% of Rev ($3.27B)
90D Engineering Disclosures
0 Published
Investor FAQ SYK vs PHG Key Questions & Quantitative Answers
Is SYK or PHG a better stock to buy right now?
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas PHG carries 28.4/100 (SELL) at $30.21 (14.9x Forward P/E, 8.8% operating margin). Technically, SYK sits in a Neutral phase (RSI 51.5, SURGE options structure) and PHG sits in a Markup phase (RSI 71.0, SURGE options structure).
Does SYK or PHG have stronger revenue and earnings growth?
SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $8.71B TTM revenue (46.4% gross margin, 8.8% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), SYK cumulative revenue shifted +7.6% while PHG shifted +2.1%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($3.27B) (0 disclosures) for PHG.
Is SYK or PHG cheaper on valuation?
PHG screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas PHG trades at 14.9x Forward P/E, 63.2x Trailing P/E, 0.90x PEG, and 3.7x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus PHG (8.6% ROE) capital efficiency.
How is options market volatility positioned on SYK vs PHG?
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, PHG carries 25.8% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.73β · 38% Vol realized risk).
Stryker Corporation (SYK) Research Suite
Koninklijke Philips N.V. (PHG) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.